Compare NATR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | LYEL |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.6M | 556.1M |
| IPO Year | 1995 | 2021 |
| Metric | NATR | LYEL |
|---|---|---|
| Price | $27.24 | $24.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $28.33 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 91.4K | 75.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $480,144,000.00 | $36,000.00 |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $4.82 | $8,712.13 |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $11.27 | $0.39 |
| 52 Week High | $28.14 | $45.00 |
| Indicator | NATR | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.31 | 59.93 |
| Support Level | $13.70 | $21.27 |
| Resistance Level | $28.00 | $27.30 |
| Average True Range (ATR) | 0.78 | 1.65 |
| MACD | 0.26 | 0.41 |
| Stochastic Oscillator | 92.69 | 90.43 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.